Please assess the completion status of the following clinical trial:

Trial Title: Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented tissue diagnosis of pancreatic ductal adenocarcinoma with a sufficient amount of tissue for Laser Capture Micro-dissection (LCM) of the stromal and tumour compartments.~* Confirmed eligibility for a Whipple's or distal pancreatectomy procedure by Multi-Disciplinary Team (MDT) and surgeon review.~* Adequate organ function defined as:~  * Creatinine clearance ≥ 50ml/min (as defined by Cockcroft-Gault)~ * Electrolytes (Sodium (Na)/Potassium (K)/Calcium (Ca)) within institutional normal limits~ * Alanine transaminase (ALT)/Aspartate transaminase (AST) \<5\*ULN~ * Partial thromboplastin time (PTT)\<2\*ULN, prior supplementation with vitamin K is allowed~ * Adequate blood counts: neutrophils \>1,500/μl, Hb \> 6mmol/L,platelets \>100.000/μl~ * Albumin ≥ 25mg/dL~* Written informed consent~* Male or female aged 18 years or over.~* World Health Organization (WHO) performance status 0-1~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.~* Males should not donate sperm during treatment or up to 3 months after the last dose.~* Women of childbearing potential are required to have a negative serum pregnancy test (with sensitivity of at least 25 mIU/mL) within 10-14 days and within 24 hours prior to the first dose of GDC-0449.~Exclusion Criteria:~* Known Hepatitis B/C or Human Immunodeficiency Virus (HIV) infection~* Known hypersensitivity to GDC-0449~* Active cardiac ischemic disease (this criterion only applies for participation in the imaging part of the study)~* Women, who are pregnant plan to become pregnant or are lactating (during the study or for up to 12 months after the last dose).~* Concurrent participation in another clinical trial using an investigational medicinal product.~* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or in the judgment of the investigator would make it undesirable for the patient to enter the trial (i.e. patients is not able to swallow tablets).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDC-0449 (Type: EXPERIMENTAL): Study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).